🔎 Trials Near Me

Hem › Myelodysplastiska syndrom › New York

Kliniska studier för Myelodysplastiska syndrom i New York

38 studier för Myelodysplastiska syndrom söker deltagare vid platser i New York.

Städer i New York

Officiell studietext (engelska)

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  • Roswell Park Cancer Institute, Buffalo
  • Stony Brook University Medical Center, Stony Brook
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT06577441

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • Memorial Sloan Kettering Cancer Center, New York
  • och 1 fler
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT06484062

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • Memorial Sloan Kettering Cancer Center, New York
RekryterarFas 1
Ålder 12 till 78 · Alla kön · Uppdaterad 29 sep. 2026 · NCT03802695

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Roswell Park Cancer Institute, Buffalo
  • Memorial Sloan Kettering Commack, Commack
  • Northwell Health/Center for Advanced Medicine, Lake Success
  • och 9 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT05564390

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

  • Memorial Sloan Kettering Cancer Center, New York
  • Icahn School of Medicine at Mount Sinai, New York
  • Montefiore, New York
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 23 sep. 2026 · NCT05320198

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  • Hematology Oncology Associates of Rockland, Nyack
  • Albert Einstein College - Montefiore, The Bronx
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 18 sep. 2026 · NCT07422480

Collection of Tissue Samples for Cancer Research

  • Roswell Park Cancer Institute, Buffalo
RekryterarObservationsstudie
2 Months · Alla kön · Uppdaterad 16 sep. 2026 · NCT00900198

A Telehealth Advance Care Planning Intervention

  • University of Rochester, Rochester
Rekryterar
Ålder 60 och äldre · Alla kön · Uppdaterad 11 sep. 2026 · NCT05875805

Cord Blood Transplant in Adults With Blood Cancers

  • Memorial Sloan Kettering Cancer Center, New York
RekryterarFas 2
Ålder 21 till 65 · Alla kön · Uppdaterad 11 sep. 2026 · NCT05884333

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Albany Medical Center, Albany
  • Maimonides Medical Center, Brooklyn
  • NYU Langone Hospital - Long Island, Mineola
  • och 7 fler
RekryterarFas 1/2
Upp till ålder 22 · Alla kön · Uppdaterad 25 aug. 2026 · NCT04726241

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  • Northwell Health, Lake Success
  • Clinical Research Alliance NY, Westbury
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 21 aug. 2026 · NCT06499285

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

  • New York Cancer and Blood, Shirley
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 21 aug. 2026 · NCT04419649

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

  • NYU Langone Health, New York
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 18 aug. 2026 · NCT06656494

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

  • Ichan School of Medicine at Mount Sinai, New York
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 10 aug. 2026 · NCT05308264

Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

  • Albany Medical Center, Albany
RekryterarObservationsstudie
Upp till ålder 30 · Alla kön · Uppdaterad 16 juli 2026 · NCT04968834

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Weill Cornell Medicine - New York Presbyterian Hospital, New York
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 7 juli 2026 · NCT07216443

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

  • Wilmot Cancer Institute, University of Rochester, Rochester
RekryterarTidig fas 1
Ålder 18 till 75 · Alla kön · Uppdaterad 3 juni 2026 · NCT03964506

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
RekryterarFas 2
Upp till ålder 26 · Alla kön · Uppdaterad 14 maj 2026 · NCT07566377

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • New York University Langone Hospital - Long Island, Mineola
  • Perlmutter Cancer Center - 34th Street, New York
  • och 2 fler
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 apr. 2026 · NCT04256317

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

  • Icahn School of Medicine at Mount Sinai, New York
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 13 apr. 2026 · NCT06146257

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

  • The University of Rochester, Rochester
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 13 apr. 2026 · NCT05732103

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

  • Memorial Sloan Kettering Cancer Center, New York
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 25 mars 2026 · NCT07107126

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Roswell Park Comprehensive Cancer Center, Buffalo
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 24 mars 2026 · NCT04988555

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

  • Montefiore Medical Center, The Bronx
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 3 mars 2026 · NCT07283094

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  • Roswell Park Cancer Institute, Buffalo
  • New York University, New York
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 16 jan. 2026 · NCT05143996

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

  • Montefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM), The Bronx
RekryterarFas 1
Ålder 18 till 75 · Alla kön · Uppdaterad 8 jan. 2026 · NCT05342584

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

  • Montefiore Medical Center, The Bronx
  • White Plains Hospital, White Plains
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 5 jan. 2026 · NCT05184842

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

  • Montefiore Medical Center, The Bronx
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 23 dec. 2025 · NCT04245397

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

  • Montefiore Medical Center, The Bronx
RekryterarFas 1Friska volontärer välkomna
Ålder 18 och äldre · Alla kön · Uppdaterad 10 nov. 2025 · NCT05986240

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Buffalo
  • Massive Bio SYNERGY-AI site, Hempstead
  • Massive Bio SYNERGY-AI site, Manhasset
  • och 2 fler
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 28 okt. 2025 · NCT03452774

Umbilical Cord Blood Transplantation From Unrelated Donors

  • Wilmot Cancer Institute, Rochester
RekryterarObservationsstudie
2 Months – 75 Years · Alla kön · Uppdaterad 10 okt. 2025 · NCT03016806

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

  • Roswell Park Cancer Institute, Buffalo
  • Memorial Sloan Kettering Cancer Center, New York
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2025 · NCT06501196

Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome

  • University of Rochester Medical Center, Rochester
RekryterarObservationsstudie
Ålder 18 och äldre · Alla kön · Uppdaterad 17 sep. 2025 · NCT01311258

Study of REM-422 in Patients With AML or Higher Risk MDS

  • Memorial Sloan Kettering, New York
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 23 apr. 2025 · NCT06297941

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

  • Memorial Sloan Kettering Cancer Center, New York
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 15 apr. 2025 · NCT06462365

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • Memorial Sloan-Kettering Cancer Center, New York
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 20 mars 2024 · NCT04243785

Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.